Church-based Intervention to Improve Blood Pressure in African Americans

Sponsor
Rush University Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT05220332
Collaborator
(none)
312
1
2
35.1
8.9

Study Details

Study Description

Brief Summary

This is a 12-month behavioral cluster-randomized trial testing a church-based intervention to reduce blood pressure in African Americans with uncontrolled blood pressure.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Heart to Heart
  • Behavioral: Money Smart
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
312 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Masking:
Double (Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Abundant Living: A Church-based Intervention to Improve Blood Pressure in African Americans
Anticipated Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2024
Anticipated Study Completion Date :
Feb 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Heart to Heart

Behavioral: Heart to Heart
The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.

Active Comparator: Money Smart

Behavioral: Money Smart
The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.

Outcome Measures

Primary Outcome Measures

  1. Change in Blood pressure [Measured at baseline and 6 months and 12 months after start of the intervention]

    The primary outcome is systolic blood pressure at 6 months post start of the intervention. The Omron digital blood pressure monitor will be utilized to measure blood pressure (Omron Healthcare, Inc., Lake Forest, IL). The participant will sit quietly for >5 minutes, 3 readings will be taken 1-2 minutes apart while seated, and an average of the last 2 readings will be taken to evaluate blood pressure.

Secondary Outcome Measures

  1. Change in Medication adherence [Measured at baseline and 6 months and 15 months after start of the intervention]

    Medication adherence will be measured using the 15-item Adherence to Refills and Medications Scale (ARMS). The items are evaluated on a 4-point scale ranging from "none of the time" to "all of the time".

  2. Change in DASH diet adherence [Measured at baseline and 6 months and 15 months after start of the intervention]

    Adherence to the Dietary Approaches to Stop Hypertension (DASH) diet will be measured using the food frequency questionnaire developed by Viocare (Princeton, NJ). This 156-item graphical, web-based FFQ queries respondents about usual intakes of 156 food and beverage items over the past three months. It also provides food and nutrient analyses to the research team based on the Nutrition Data System for Research 2018 (NDSR, University of Minnesota, Minneapolis, MN).

  3. Change in Self efficacy [Measured at baseline and 6 months and 15 months after start of the intervention]

    Self efficacy will be measured using the Hypertension Self-Care Profile Self-efficacy scale which evaluates self efficacy for 8 common self care recommendations for individuals with hypertension. The items are evaluated on a 4-point scale ranging from "not confident" to "very confident".

  4. Change in Quality of life [Measured at baseline and 6 months and 15 months after start of the intervention]

    Quality of life will be measured using the EuroQual (EQ-5D-5L) questionnaire. The measure evaluates the participant's perception of their "health today" with respect to mobility, self-care, usual activities, pain/discomfort, and anxiety depression. The items are evaluated on a 5-point scale ranging from "no problem" in the area to "extreme problem" in the area.

  5. Change in Social support [Measured at baseline and 6 months and 15 months after start of the intervention]

    Social support for eating a healthy diet will be measured using a 4-item questionnaire which will evaluate the participant's perception of social support received from family members, friends, church members, and their Pastor. The items are evaluated on a 5-point scale ranging from "never" to "always".

  6. Change in Hypertension knowledge [Measured at baseline and 6 months and 15 months after start of the intervention]

    Hypertension knowledge will be evaluated using a 10-item questionnaire adapted from the Hypertension Evaluation of Lifestyle and Management (HELM) Knowledge Scale. Systolic and diastolic blood pressure measurements will be evaluated using the following 4 categories: high, low, normal, and don't know. The frequency with which medication should be taken, lifestyle factors associated with hypertension, and health risks associated with hypertension will also be evaluated.

  7. Change in Nutrition knowledge [Measured at baseline and 6 months and 15 months after start of the intervention]

    Nutrition knowledge will be evaluated using an 18-item survey adapted from the International Food Policy Study 2020 - United States Survey. Common foods and food labels are evaluated on a 10-point scale ranging from "not healthy at all" to "extremely healthy".

  8. Change in Barriers to medication use [Measured at baseline and 6 months and 15 months after start of the intervention]

    Barriers to medication use will be measured using the 15-item BRIGHT study Barriers to Medication Scale. The scale evaluates different reasons why it is difficult for participants to take medications or to take the medications on time. The items are evaluated on a 5-point scale ranging from "never" to "all the time".

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Churches:
  • At least 75 members and ability to recruit 15 study participants

  • Predominantly African American congregants

Participants:
  • Age 18 or older

  • Has blood pressure readings with uncontrolled blood pressure, defined as exceeding the blood thresholds for initiation of antihypertensive medication according to the 2017 American College of Cardiology/ American Heart Association (ACC/AHA) guidelines.

  • The thresholds are 140/90 for the general population < 65 years old, and 130/80 for individuals ≥ 65 or with diabetes, chronic kidney disease, or high cardiovascular risk (self-report of prior diagnosis of myocardial infarction, coronary heart disease, stroke or heart failure)

  • Attends church (virtually or in-person) at least once per month

  • Able to attend weekly Zoom meetings

  • Consents and completes all baseline assessments

Exclusion Criteria:
Churches:

• Pastor unwilling to conduct Bible study

Participants:
  • Unable to make dietary changes due to lack of control over their food source (i.e., eat meals at shelter, nursing home)

  • Has a medical condition that prohibits or severely restricts ability to eat vegetables (i.e., renal disease, Crohn's disease)

  • Has a medical condition with an uncertain 6-month prognosis

  • Inability to give informed consent (i.e., cognitive impairment, does not speak Englis

  • Plans to move within the 6 months following enrollment

  • Participated in prior ALIVE intervention

  • Member of household participating in another church

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rush University Medical Center Chicago Illinois United States 60422

Sponsors and Collaborators

  • Rush University Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Elizabeth Lynch, Associate Professor, Rush University Medical Center
ClinicalTrials.gov Identifier:
NCT05220332
Other Study ID Numbers:
  • 18050306
First Posted:
Feb 2, 2022
Last Update Posted:
Feb 2, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 2, 2022